Document Detail

Restrictive organic mitral regurgitation associated with benfluorex therapy.
MedLine Citation:
PMID:  20237052     Owner:  NLM     Status:  MEDLINE    
AIMS: To investigate the association between benfluorex use and organic restrictive mitral regurgitation (MR) in patients admitted to hospital for diagnostic work-up of MR of unclear aetiology.
METHODS AND RESULTS: Among patients referred between 2003 and 2008 to our tertiary centre for diagnostic work-up of MR, we retrospectively identified 22 consecutive patients (65 +/- 12 years, 64% women) with restrictive organic MR of unclear aetiology. Using propensity scores, 22 out of 156 patients who underwent surgery for dystrophic MR due to flail leaflets during the same time period were matched for age, sex, height, body weight, and diabetes with the study population. Eight of the 22 patients with restrictive organic MR of unclear aetiology (36.4%) had a history of benfluorex use, and in one patient (4.5%) we identified previous exposure to both benfluorex and fenfluramine. The frequency of benfluorex treatment in patients with restrictive organic MR of unclear aetiology was significantly higher compared with that observed in the dystrophic MR group (36.4 vs. 4.5%; P-value 0.039). Patients with restrictive MR treated with benfluorex (body mass index 31 +/- 6 kg/m(2)) were all dyslipidaemic and 67% had diabetes. Echocardiography identified moderate or severe restrictive organic MR in all cases. Median total duration of benfluorex therapy was 63(12-175) months, at a daily dose of 450 (300-450) mg, leading to a cumulative dose of 850 (108-2363) g.
CONCLUSION: Although it cannot affirm a definitive causal relationship, the present study strongly suggests that patients treated with benfluorex might incur a risk of restrictive organic valvular heart disease. Therefore, echocardiography should be performed in patients exposed to benfluorex in case of occurrence of symptoms or signs of valvular disease. Further data are needed to confirm these findings.
Christophe Tribouilloy; Dan Rusinaru; Pierre Henon; Laurence Tribouilloy; François Leleu; Michel Andréjak; Henri Sevestre; Marcel Peltier; Thierry Caus
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2010-03-17
Journal Detail:
Title:  European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology     Volume:  11     ISSN:  1532-2114     ISO Abbreviation:  Eur J Echocardiogr     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-06     Completed Date:  2010-12-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100890618     Medline TA:  Eur J Echocardiogr     Country:  England    
Other Details:
Languages:  eng     Pagination:  614-21     Citation Subset:  IM    
Department of Cardiology, University Hospital Amiens, Amiens, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Appetite Depressants / administration & dosage,  adverse effects*
Body Mass Index
Cardiomyopathy, Restrictive / chemically induced*,  surgery,  ultrasonography
Diabetes Mellitus / drug therapy
Drug Therapy, Combination
Dyslipidemias / drug therapy
Echocardiography, Doppler, Color
Fenfluramine / administration & dosage,  adverse effects*,  analogs & derivatives*
Hospitals, University
Medical Records
Middle Aged
Mitral Valve Insufficiency / chemically induced*,  surgery,  ultrasonography
Obesity / drug therapy
Retrospective Studies
Serotonin Uptake Inhibitors / administration & dosage,  adverse effects*
Time Factors
Reg. No./Substance:
0/Appetite Depressants; 0/Serotonin Uptake Inhibitors; 23602-78-0/benfluorex; 458-24-2/Fenfluramine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Women who gave birth to girls with Turner syndrome: maternal and neonatal characteristics.
Next Document:  The importance of papillary muscle dyssynchrony in predicting the severity of functional mitral regu...